Referring Clinicians

Trials Recruiting at ACTC 

Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
Advanced Solid Organ TumoursGILEAD (GS-US-494-5484)A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in
Subjects with Advanced Solid Tumors
GS-4224 (small molecule oral PDL1 Inhibitor)
Daily dosing, 3 week cycles
Advanced Solid Organ Malignancy with no further treatment options.

- Biopsy substudy (1000mg daily):
CPS >10% on pre-screening of archival tissue

- Dose Escalation Cohort (1000mg BD): Checkpoint inhibitor naïve metastatic melanoma, NSCLC, clear cell RCC, urothelial, gastric, HNSCC, hepatocellular carcinoma, Merkel cell, esophageal SCC, cutaneous SCC and MSI-H cancers (each tumour type has a pre-specified TPS levels for eligibility)
Both cohorts recruiting
Oesophageal SCCNP40435Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumoursPD1/TIM3 bi-specific antibody

2 weekly infusions
- Oesophageal: squamous or adeno-squamous, not more than 1 line of treatment for metastatic disease or recurrence within 24 weeks after chemo-RT/ surgical resection. Recruiting
CervicalAK104-201-AUA Phase 2, global, multicenter, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.AK104
(bispecific antibody targeting CTLA4/ PD-1)

Fortnightly infusion
•Previously treated recurrent or metastatic squamous carcinoma or adeno-squamous carcinoma of the cervix:
o Disease progression during or following platinum doublet
o No more than 2 prior systemic therapies in recurrent/ metastatic setting
o Not eligible for surgery or radiation as treatment for recurrent disease
o Available archival tissue for PD-L1 assessment.
NSCLC, RCCCA20976UA Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab
and in Combination with Subcutaneous Nivolumab
S/C Ipilimumab (6 weekly) + S/C Nivolumab (2 weekly) administered with rHuPH20 (recombinant human hyaluronidase)Part 2
o Metastatic NSCLC: Opening soon. Treatment naïve stage IV . Prior adjuvant chemo +/- RT allowed as long as > 6 months from time of completion.
o RCC: No prior treatment lines for stage IV or recurrent disease, IMDC intermediate and poor risk only.
Opening soon
Advanced solid tumours with established IO indicationBGB-A317-A445-101Phase 1 Study Investigating the Safety, Tolerability,
Pharmacokinetics, and Preliminary Antitumor Activity of the
Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in
Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab
in Patients With Advanced Solid Tumors
BGB-A445 (OX40 agonist) and Tislelizumab (PD-1 inhibitor)

Three weekly infusions
• Phase 1a: Dose Escalation: Includes BGB-A445 monotherapy cohorts and combination cohorts with tislelizumab. Recruitment opens intermittently.

• Dose Expansion: Closed until phase 1a completed. Details to follow.
Phase 1a recruiting
Metastatic MelanomaMK1308-001 (Checkmate 76U)A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab
Monotherapy and in Combination with Subcutaneous Nivolumab
MK1308A (Co-formulation of MK1308 (CTLA4 inh) + pembrolizumab-Cohort J
o Unresectable stage III or metastatic melanoma
o Confirmed progression on scan after PD1/PDL1 monotherapy or in combination with other therapies excluding prior CTLA4 inhibitor exposure.
o BRAF v600 mutation positive disease accepted provided that participants have/ are still receiving targeted therapy OR remains asymptomatic with no evidence of rapid progression and LDH
Opening soon

How to Refer 

Please email all referrals to (include Att: ACTC in email subject)

Email us for any other inquiries:


Auckland Cancer Trials Centre

Auckland City Hospital,

2, Park Road, Grafton,

1023, Auckland, New Zealand

Patient Referrals 

Please email all referrals to: (include Att: ACTC in email subject)

Email us for any other inquiries: